Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Stereotaxis (NYSE: STXS) announced that its latest GenesisX robotic system is being featured at Neusoft Medical Systems' booth during RSNA 2024, the world's premier radiology forum in Chicago. The system is being showcased alongside Neusoft's NeuAngio 30F fluoroscopy system, marking a growing collaboration between the companies to integrate and commercialize complementary technologies.
GenesisX builds upon Robotic Magnetic Navigation technology, aiming to enhance precision, efficiency, and safety in endovascular procedures while reducing hospital adoption barriers. The event, attended by over 50,000 professionals from 150+ countries, represents the first public showcase of the GenesisX system.
Stereotaxis (NYSE: STXS) ha annunciato che il suo ultimo sistema robotico GenesisX verrà presentato presso lo stand di Neusoft Medical Systems durante il RSNA 2024, il principale forum mondiale di radiologia a Chicago. Il sistema sarà esposto insieme al sistema di fluoroscopia NeuAngio 30F di Neusoft, segnando una crescente collaborazione tra le aziende per integrare e commercializzare tecnologie complementari.
GenesisX si basa sulla tecnologia di Navigazione Magnetica Robotica, con l'obiettivo di migliorare precisione, efficienza e sicurezza nelle procedure endovascolari, riducendo al contempo le barriere all'adozione ospedaliera. L'evento, a cui parteciperanno oltre 50.000 professionisti provenienti da più di 150 paesi, rappresenta la prima vetrina pubblica del sistema GenesisX.
Stereotaxis (NYSE: STXS) anunció que su último sistema robótico GenesisX se presentará en el stand de Neusoft Medical Systems durante el RSNA 2024, el principal foro de radiología del mundo en Chicago. El sistema se exhibirá junto al sistema de fluoroscopia NeuAngio 30F de Neusoft, marcando una creciente colaboración entre las empresas para integrar y comercializar tecnologías complementarias.
GenesisX se basa en la tecnología de Navegación Magnética Robótica, con el objetivo de mejorar la precisión, la eficiencia y la seguridad en los procedimientos endovasculares, al tiempo que reduce las barreras para la adopción hospitalaria. El evento, que contará con la asistencia de más de 50,000 profesionales de más de 150 países, representa la primera muestra pública del sistema GenesisX.
스테레오택시스 (NYSE: STXS)는 최신 제너시스X 로봇 시스템이 시카고에서 열리는 세계 최고의 영상의학 포럼 RSNA 2024에서 뉴소프트 메디컬 시스템의 부스에서 전시된다고 발표했습니다. 이 시스템은 뉴소프트의 뉴앙지오 30F 형광 투시 시스템과 함께 전시되어 두 회사 간의 상호 보완적인 기술을 통합하고 상용화하려는 협력이 확대됨을 나타냅니다.
제너시스X는 로봇 자기 내비게이션 기술을 기반으로 하여, 정맥 내 시술의 정밀성, 효율성 및 안전성을 높이고 병원에서의 도입 장벽을 줄이는 것을 목표로 하고 있습니다. 150개국 이상에서 5만 명 이상의 전문가가 참석하는 이번 행사는 제너시스X 시스템의 첫 공개 전시회가 됩니다.
Stereotaxis (NYSE: STXS) a annoncé que son dernier système robotique GenesisX sera présenté au stand de Neusoft Medical Systems lors du RSNA 2024, le premier forum mondial de radiologie à Chicago. Le système sera exposé aux côtés du système de fluoroscopie NeuAngio 30F de Neusoft, marquant une collaboration croissante entre les entreprises pour intégrer et commercialiser des technologies complémentaires.
GenesisX repose sur la technologie de Navigation Magnétique Robotique, visant à améliorer la précision, l'efficacité et la sécurité lors des procédures endovasculaires tout en réduisant les barrières à l'adoption hospitalière. L'événement, auquel participent plus de 50 000 professionnels issus de plus de 150 pays, représente la première vitrine publique du système GenesisX.
Stereotaxis (NYSE: STXS) hat angekündigt, dass ihr neuestes GenesisX Robotersystem während der RSNA 2024, dem weltweit führenden Forum für Radiologie in Chicago, am Stand von Neusoft Medical Systems präsentiert wird. Das System wird zusammen mit Neusofts NeuAngio 30F Fluoroskopie-System vorgestellt, was eine wachsende Zusammenarbeit zwischen den Unternehmen zur Integration und Vermarktung komplementärer Technologien markiert.
GenesisX baut auf der Robotic Magnetic Navigation-Technologie auf und zielt darauf ab, Präzision, Effizienz und Sicherheit bei endovaskulären Verfahren zu verbessern und gleichzeitig die Hürden für die Einführung im Krankenhaus zu verringern. Die Veranstaltung, an der über 50.000 Fachleute aus mehr als 150 Ländern teilnehmen werden, stellt die erste öffentliche Präsentation des GenesisX-Systems dar.
- Growing collaboration with Neusoft Medical Systems, a global leader with 47,000 installed systems
- First public showcase of GenesisX system at major industry event RSNA
- Potential market expansion through integration with Neusoft's medical imaging solutions
- None.
Insights
The showcase of GenesisX at RSNA 2024 alongside Neusoft Medical Systems represents a strategic partnership that could significantly expand Stereotaxis' market reach, particularly in Asia. The collaboration with Neusoft, which has 47,000 installed systems globally, provides a substantial distribution channel and integration opportunity for Stereotaxis' robotic technology.
The GenesisX system's design focuses on reducing adoption barriers while maintaining the core benefits of Robotic Magnetic Navigation. This approach addresses a critical market challenge - the complexity and cost of implementing robotic surgical systems. Integration with Neusoft's NeuAngio 30F fluoroscopy system could create a more compelling complete solution for hospitals, potentially accelerating market adoption.
This partnership signals a strategic pivot for Stereotaxis to expand its global footprint, particularly leveraging Neusoft's strong presence in the Chinese healthcare market. The timing is significant as China's medical device market is experiencing rapid growth, driven by healthcare reforms and increasing demand for advanced medical technologies.
The debut at RSNA, with its 50,000+ attendees from 150+ countries, provides exceptional visibility for the GenesisX system. The collaboration with an established player like Neusoft could help overcome market entry barriers and accelerate commercialization efforts, potentially leading to increased market share and revenue growth in the medium term.
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis’ latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems’ booth at the Radiology Society of North America’s (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.
RSNA is the premier annual radiology forum in the world, with over 50,000 attendees from over 150 countries. Neusoft Medical Systems is a global leader in advanced medical imaging solutions, with over 47,000 installed systems that provide high-quality care to patients and healthcare providers globally. Stereotaxis’ GenesisX System, the latest innovation in endovascular robotics, is being showcased for the first time alongside Neusoft Medical Systems’ NeuAngio 30F fluoroscopy system. Presence at RSNA reflects a growing collaboration between Stereotaxis and Neusoft Medical Systems to integrate and commercialize complementary technologies. GenesisX builds upon the well-established benefits of Robotic Magnetic Navigation technology, while reducing complexities and barriers to hospital adoption. This system is designed to enhance precision, efficiency, and safety across a broad range of endovascular procedures.
“Neusoft Medical Systems is committed to providing advanced high-quality medical technologies that improve healthcare globally,” said Patrick Wu, CEO of Neusoft Medical Systems. “Stereotaxis’ revolutionary GenesisX robotic technology aligns well with our portfolio of advanced innovative imaging systems and we are pleased to collaborate with Stereotaxis and showcase our joint solutions at RSNA 2024.”
“We very much appreciate the invitation by Neusoft Medical Systems to demonstrate GenesisX at RSNA and are excited to showcase our joint technologies for the first time at a conference of this caliber,” said David Fischel, CEO of Stereotaxis. “GenesisX promises to have a profound impact on the trajectory of endovascular robotics. We look forward to our expanded collaboration with Neusoft Medical Systems helping deliver groundbreaking technologies to patients globally.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is Stereotaxis (STXS) showcasing at RSNA 2024?
What are the key features of Stereotaxis (STXS) GenesisX system?
What is the collaboration between Stereotaxis (STXS) and Neusoft Medical Systems?
